CTOs on the Move

MARATHONLS

www.marathonls.com

 
Marathon Life Sciences Laboratory Solutions at the Speed of Science Learn more Our Lab Supplies Line Cell Strainer Download Catalogadd to cart Tissue Culture Plates Download Catalog 15/50mL Centrifuge Tubes Download Catalog Petri Dishes Download Catalo...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Lab Co Inc

Lab Co Inc is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clinical Research Consultants

Clinical Research Consultants is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RiboCor

RiboCor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Applied Technology Holdings

ATH's sales and technology groups build custom wireless turn-key technology solutions that relate to specific customer body motion measurement needs and market opportunities. ATH's vision is to commercialize it's patent portfolio and lead the industry in distributed wireless bioMotion technology and data capture processes. Founded in 2005, Applied Technology Holdings Inc., is a hardware and software maker specializing in wireless bioMotion monitoring systems for medical, sports, gaming, military and aviation applications. ATH's subsidiaries are experts in supporting the solution provider platforms for easy integration into the target markets. Other ATH companies participate in the Sports, Medical, Gaming, Aviation, and Military market opportunities and segments.

Triplet Therapeutics

Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington`s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.